Blocking of the Gut Hormone Receptor for Glucagon-like Peptide 2 (GLP-2) by the GLP-2 Receptor Antagonist GLP-2(3-33)

Ten healthy participants will meet fasting and attend four randomized experimental days of MRI-scans of the abdomen. Each day will include subcutaneous injections of GLP-2 or saline and intravenous infusion of either the GLP-2 (3-33) antagonist or saline. The infusion start at timepoint -20, while the subcutaneous injection is given to timepoint 0 and the participant will lay in the scanner in one hour after injection. Eight MR-scans are done repeatedly to measure the blood flow in larger abdominal vessels and four blood samples are taken during the experimental day for analysis of GLP-2(1-33), GLP-2(3-33) and bone markers.

Inclusion criteria

• Age 18-70 years
• BMI 19-28 kg/m2

Exclusion criteria

• Chronic illness that affects the cardiovascular system or gastrointestinal tract
• Treatment with medicine or supplements that cannot be paused for 12 hours
• Intake of above 14 alcoholic drinks per week or substance abuse
• Liver enzymes (ALAT) above 2 times normal values
• Decreased kidney function (eGFR below 90 or creatinine levels over reference value)
• Low blood percentage (hemoglobin below reference value)
• Any condition or disease that the persons responsible for the study find would interfere with the participation of the study.